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Multiple Myeloma
Introduction
Multiple myeloma (MM) is a plasma cell malignancy char-
acterized by high genetic complexity.1 The development of
high-throughput methodologies for genomic analysis has
greatly increased our understanding of the pathogenesis of
MM. These techniques show that genetic heterogeneity ulti-
mately results in different gene expression profiles specific to
singular genetic abnormalities. Thus, the recurrent IGH
translocations, the most frequent gains and losses, as well as
the hyperdiploid and non-hyperdiploid categories display
specific expression signatures.2-7
Based on clinical and biological data, a multistep model of
disease progression has been proposed, starting in monoclon-
al gammopathy of undetermined significance (MGUS) con-
tinuing through MM, sometimes with an intermediate entity
called smoldering MM (SMM), and ending in extramedullary
disease.8-11 Cytogenetic studies using fluorescence in situ
hybridization analysis (FISH) and more sophisticated genom-
ic technologies, such as SNP-based mapping arrays and whole
genome sequencing have provided a framework of the recur-
rent chromosomal abnormalities associated with the evolving
stages of monoclonal gammopathies, and highlighted that
most genetic lesions typical of MM are already present in
MGUS and SMM steps.12-16 We have shown that a major dif-
ference among these three entities is the number of clonal PC
with genetic abnormalities that increases from MGUS to
SMM and to MM, suggesting a clonal expansion of genetical-
ly abnormal PC.17,18 Regarding progression genetic markers, it
has been recently shown that specific chromosomal abnor-
malities, such as del(17p), t(4;14), 1q gains and hyperdiploidy
significantly predict progression to active MM in SMM
patients.19,20 
GEP has also been used for identifying genes deregulated in
the transition from normal plasma cells (NPC) to MGUS and
MM.6,10,21-23 In this setting, it has been shown that the number
of genes differentially expressed between NPC and MGUS is
significantly higher than those deregulated between MGUS
and MM,10,22 although these two diseases could be differenti-
ated based on expression of genes mainly involved in metab-
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A multistep model has been proposed of disease progression starting in monoclonal gammopathy of undetermined
significance continuing through multiple myeloma, sometimes with an intermediate entity called smoldering
myeloma, and ending in extramedullary disease. To gain further insights into the role of the transcriptome deregu-
lation in the transition from a normal plasma cell to a clonal plasma cell, and from an indolent clonal plasma cell to
a malignant plasma cell, we performed gene expression profiling in 20 patients with monoclonal gammopathy of
undetermined significance, 33 with high-risk smoldering myeloma and 41 with multiple myeloma. The analysis
showed that 126 genes were differentially expressed in monoclonal gammopathy of undetermined significance,
smoldering myeloma and multiple myeloma as compared to normal plasma cell. Interestingly, 17 and 9 out of the
126 significant differentially expressed genes were small nucleolar RNA molecules and zinc finger proteins. Several
proapoptotic genes (AKT1 and AKT2) were down-regulated and antiapoptotic genes (APAF1 and BCL2L1) were up-
regulated in multiple myeloma, both symptomatic and asymptomatic, compared to monoclonal gammopathy of
undetermined significance. When we looked for those genes progressively modulated through the evolving stages
of monoclonal gammopathies, eight snoRNA showed a progressive increase while APAF1, VCAN and MEGF9
exhibited a progressive downregulation. In conclusion, our data show that although monoclonal gammopathy of
undetermined significance, smoldering myeloma and multiple myeloma are not clearly distinguishable groups
according to their gene expression profiling, several signaling pathways and genes were significantly deregulated at
different steps of the transformation process.
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ABSTRACT
olism and proliferation.6 Regarding SMM, there has been
no attempt to define an expression signature able to dis-
criminate asymptomatic and symptomatic MM. Probably,
the blurred limit between the established criteria for dis-
tinguishing MGUS, SMM and MM hampers the identifi-
cation of characteristic expression patterns of the multi-
step transformation process. 
Our aim was to gain further insights into the transcrip-
tome deregulation observed in clonal PC from MGUS,
SMM and symptomatic MM compared to NPC, and in
addition, to find out whether the different evolving steps
of monoclonal gammopathies display a singular expres-
sion signature.
Methods
Patients and samples
Bone marrow (BM) samples were obtained from 20 patients
with MGUS, 33 with high-risk SMM and 41 with MM. All sam-
ples corresponded to newly diagnosed untreated patients. To
avoid misclassification or overlapping entities, we decided to focus
on MGUS patients with more than two years of stable follow up.
Samples were classified according to the International Myeloma
Working Group criteria.24 The criteria for defining high-risk SMM
has been described previously.18,25 In addition, 5 healthy donors
were also included in order to relate the deregulation of gene
expression profiling of clonal populations to normal condition.
The study was approved by the research ethics committees of all
participating institutions and written informed consent was
obtained from all patients in accordance with the Declaration of
Helsinki. The main clinical and laboratory characteristics of these
patients are shown in Online Supplementary Table S1. The FISH,
SNP arrays and GEP of the patients with high-risk SMM as well as
FISH analysis of the remaining samples have been previously
reported.17,26 The frequency of the genetic abnormalities of the
patients included in the present study is indicated in Online
Supplementary Table S2.
In all the samples, a CD138-positive PC isolation using the
AutoMACs separation system (Miltenyi-Biotec) was carried out.
Final purity was over 95% in all MM and SMM cases, and over
90% in MGUS patients and healthy donors. 
RNA extraction and microarray hybridization
Total RNA was extracted using the RNeasy Mini Kit according
to the manufacturer’s instructions. The RNA integrity was
assessed using Agilent 2100 Bioanalyzer (Agilent). RNA labeling
and microarray hybridization to Human Gene 1.0 ST Array
(Affymetrix) have been previously reported.27 Full microarray data
are available at the Gene Expression Omnibus
(www.ncbi.nlm.nih.gov/geo/, accession n: GSE47552). 
Gene expression data analysis
Data pre-processing
Data pre-processing: normalization was carried out by using the
expression console (Affymetrix) with RMA algorithm which
includes background correction, normalization and calculation of
expression values (log2).28 Since myeloid contamination signature
can be detected even in samples with high purity, those probes
identifying genes exclusive of myeloid lineage were subtracted
from the analysis from the outset (Online Supplementary Table S3). 
Unsupervised analysis
The package pvclust (http://www.is.titech.ac.jp/shimo/prog/pvclust/)
was used for the calculations of hierarchical clustering analysis
with P values for all clusters, using the Euclidean distance as dis-
tance measure and the group average link method. The hypothesis
that "the cluster does not exist" was rejected with a significance
level of 0.05.
Supervised analysis
Significant Analysis of Microarrays (SAM) algorithm
(http://www-stat.standford.edu/-tibs/SAM) was used to identify
genes with statistically significant changes in expression between
different classes.29 All data were permutated over 1000 cycles by
using the two-class and multiclass response format, without con-
sidering equal variances. Significant genes were selected based on
the lowest q-value (q-value < 10-5).
Gene function analysis
The probe sets were functionally annotated and grouped
according to their biological function using Gene Ontology biolog-
ical process descriptions. The functional analysis to identify the
most relevant biological mechanisms, pathways and functional
categories in the data sets of genes selected by statistical analysis,
was generated through the use of IPA (Ingenuity Systems,
www.ingenuity.com).
Comparative analysis with other gene expression
datasets
In order to validate the supervised analysis of the present gene
expression data, two datasets including NPC, MGUS, SMM and
MM samples were generated from records of three series belong-
ing to two different institutions publicly available at Gene
Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/): GEO
GSE5900 and GSE2658 (UAMS: NPC=22, MGUS=44, SMM=12
and MM=256) and GEO GSE6477 (Mayo Clinic: NPC=15,
MGUS=22, SMM=24 and MM=73). The approaches used for
comparative analysis are detailed in the Online Supplementary
Appendix.
Quantitative real-time PCR
Methodology is described in the Online Supplementary Appendix.
Results
In a first approach to the gene expression data set, we
explored the separation of the samples into clusters based
on similarities in gene expression by using unsupervised
hierarchical clustering. Despite the fact that the four sam-
ple classes were not clearly grouped in separated branches,
the five NPC samples were clustered next to one another
and included in a subbranch (Figure 1). 
Then, we investigated whether the selected PC popula-
tion from monoclonal gammopathy patients displayed
specific expression profiles that were clearly distinguish-
able from PC from healthy donors. In order to avoid an
imbalance in the analysis when comparing 5 NPC with
more than 90 samples of clonal PC, and to avoid a poten-
tial selection of genes strongly deregulated in only one of
the groups and therefore significant in the comparison
with NPC, we considered it more appropriate to compare
separately each of the three entities with the group of
NPC to subsequently cross the three comparisons and
select the intersection genes. Finally, we looked for genes
deregulated in MGUS compared to MM, SMM compared
to MM and MGUS compared to SMM, in order to identify
gene categories and molecular pathways involved in MM
development. Since SMM category included high-risk
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asymptomatic patients, we also investigated the common
deregulated genes in SMM and MM patients compared to
the indolent MGUS state.
Expression signature of clonal PC related to normal
status
We identified a set of 126 common genes differentially
expressed in MGUS, SMM and MM as compared to NPC
(q-value < 10-5), the majority of them (106 genes) down-
regulated in clonal PC (Online Supplementary Table S4).
Further functional analysis of these 126 genes showed that
the two most significant molecular and cellular functional
categories were those related with cell cycle (ATF2,
GADD45A, CDC6 and IL-16) and cell death (BCL2L1,
CD81, CDC6, IGHM, ABCC1, ATF2 and ATXN2) (P<0.01). 
On the other hand, the top three canonical pathways
(well characterized metabolic and cell signaling pathways)
were EIF2 signaling, regulation of EIF4 and p70S6K signal-
ing, and mTOR signaling (P<0.001). These pathways play
critical roles in translational regulation and the most differ-
entially expressed genes contained in them belonged to
ribosomal protein family. Other relevant canonical path-
ways involved in the transition from NPC to clonal PC
were several interleukin signaling pathways, B-cell devel-
opment, glucocorticoid receptor signaling, G2/M DNA
damage checkpoint regulation and ATM, ERK5, VEGF, P53
and SAPK/JNK signaling pathways (P<0.05). 
Interestingly, 17 and 9 out of the 126 significant differ-
entially expressed genes were small nucleolar RNA mole-
cules (snoRNA) and zinc finger proteins, respectively. Both
groups of genes were down-regulated in the comparison
between healthy PC and monoclonal gammopathies PC
(Figure 2).
When we looked at the top 10 up-regulated and down-
regulated genes, we found important genes involved in
cancer pathogenesis (Figure 3). The most significant
under-expressed gene in clonal PC compared to NPC was
CABLES and the most significant up-regulated gene was
GEP in monoclonal gammopathies
haematologica | 2014; 99(8) 1367
Figure 1. Dendrogram from a hierarchi-
cal clustering analysis of the 99 samples
based on the expression of 13,060
probe sets passing the variation filter.
NPC: normal plasma cells; MGUS: mono-
clonal gammopathy of undetermined
significance; SMM: smoldering multiple
myeloma; MM: multiple myeloma.
*P<0.05.
Figure 2. Expression levels of several small nucleolar RNA and zinc finger proteins in plasma cells from healthy donors, MGUS, SMM and MM
patients.
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GADD45A. It is important to note that 5 (RPS28, RPS10,
RPS17, RPS12 and RPS27A) of the top 10 up-regulated
genes belonged to ribosomal protein family. TMSB10
gene, also up-regulated in clonal PC, is associated with
tumor progression and metastasis in several cancers
through JNK activation.30 
Genes differentially expressed between MGUS and MM 
A total of 1184 genes were differentially expressed
between MGUS and MM samples (642 genes were down-
regulated and 542 were up-regulated in MM). The func-
tional analysis revealed that the molecular and cellular
function the most significantly affected in the comparison
between MGUS and MM was cell death, with 106 genes
involved (P<0.01). When the genes included in this catego-
ry were evaluated according to their anti or proapoptotic
role, an imbalance in favor of antiapoptotic state was
observed in MM. Thus, AKT1 and AKT2, antiapoptotic
genes, were over-expressed in MM compared to MGUS.
In fact, (PI3K)/Akt pathway has been reported to con-
tribute to the malignant growth of MM.31 The upregula-
tion of BAG3 and GADD45B in MM also contribute to the
antiapoptotic state of this disease.32,33 Moreover, APAF1
(one of the most down-regulated genes with an FC of 6.9)
and BCL2L1, which are apoptotic activators, were down-
regulated in MM as compared to MGUS.34,35
The canonical pathway most statistically significant and
with the highest number of genes corresponded to EIF2,
which catalyzes the first regulated step of protein synthesis
initiation.36 Several ribosomal proteins were included in this
pathway. IL-8 signaling was also at the top of the most sig-
nificant canonical pathway list and, interestingly, another
five significant canonical pathways involved interleukins
(IL-8, IL-17A, IL-6, IL-15, IL-10 and IL-4). One of the top 10
genes up-regulated in MM compared to MGUS was TERC. 
Genes differentially expressed between SMM and MM 
In the SMM versus MM comparison, 1163 genes were
significantly deregulated (936 genes were down-regulated
and 227 were up-regulated in MM). DNA replication,
recombination and repair, containing 16 genes, were the
most significant deregulated molecular and cellular func-
tion. ATM and RAD17, important cell cycle checkpoint
genes, together with RAD50, which are directly involved
in DNA damage repair, were included in this molecular
function.37
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Figure 3. Expression of the top 10 up-regulated and down-regulated
genes from the comparison between clonal plasma cells and normal
plasma cells. 
Figure 4. Expression of the genes significantly deregulated among
the three entities.
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Telomere extension by telomerase, Myc mediated apop-
tosis, insulin receptor, IGF1, p53, NF-kB, TGFb and
Jak/stat signaling were included within the most signifi-
cant canonical pathways. Myc mediated apoptosis signal-
ing is of particular interest, as it is frequently associated
with human malignancies, including MM.21 This pathway
involved genes like the proapoptotic BAD, the adapter
molecule for the death receptor family FADD and caspase
8, among others.35
Genes differentially expressed between MGUS 
and SMM 
The analysis showed that a set of 627 differentially
expressed genes was able to differentiate MGUS from
SMM (q-value < 10-5) (237 genes were down-regulated in
SMM and 390 were up-regulated). Similarly to the com-
parison between MGUS and MM, cell death was identi-
fied as the most significant molecular function affected in
the transition from MGUS to SMM, based on the deregu-
lation of 55 genes (P<0.01). For example, the proapoptotic
gene APAF1was down-regulated in SMM patients and the
antiapoptotic genes BAG1 and BAG3were over-expressed
in SMM. 
The RAC and NFKB signaling (P<0.01) were included
within the top canonical pathways. RELA, a NFKB compo-
nent, is a pleiotropic transcription factor involved in many
biological processes, such as cell growth, tumorigenesis
and apoptosis.38 Within the top 10 down-regulated genes,
ERGwas one of the most under-expressed genes in SMM.
ERG is a key regulator of cell proliferation and differentia-
tion, and angiogenesis.39 Regarding the top 10 over-
expressed genes, RPL7A is a ribosomal protein and an
altered pattern of RPL7 expression has been described in
colorectal carcinoma.40
Genes differentially expressed between MGUS
and myeloma disease (SMM/MM)
After analyzing the gene expression differences
between MGUS, SMM and MM, and since high-risk
smoldering myeloma is an entity very close to sympto-
matic myeloma, we wanted to focus on those genes that
characterize the myeloma disease compared to the indo-
lent MGUS state. A set of 275 genes commonly deregulat-
ed in SMM and MM was able to distinguish the myeloma
disease (SMM and MM) from MGUS (q-value < 10-5).
Cell death and survival was identified as the most signif-
icant molecular function affected in the transition from
MGUS to myeloma disease, based on the deregulation of
35 genes (P<0.01), such as the antiapoptotic gene BAG3
and the NFKB component RELA (both up-regulated in
SMM and MM). Similar to a comparison of MGUS versus
SMM, the RAC signaling pathway deregulation (P<0.01)
was included within the five most significant canonical
pathways (RELA, NFKBIA, MAPK1, CEBPD, LCN2 and
IL17RA). 
Genes with progressive modulation from MGUS 
to SMM and to MM
Finally, we also looked for those genes significantly
deregulated among the three entities, which in turn were
progressively up- or down-regulated from MGUS to SMM
and to MM. We reasoned that these genes could be the
most significant for promoting multistep transformation.
Surprisingly, only 11 out of the 2335 significant genes
exhibited a progressive deregulation (P<0.0001) in the
evolving stages of monoclonal gammopathies. All the
genes with a progressive increase from MGUS to SMM
and to MM were small nucleolar RNA genes (snoRNA)
(Figure 4). In addition, only 3 genes, APAF1, VCAN and
MEGF9, showed a progressive downregulation in the
transition from MGUS to SMM and to MM (Figure 4). All
the 3 genes have been described to be involved in cancer:
APAF1 encodes a cytoplasmic protein that initiates apop-
tosis, and decreased expression of this gene has been
reported in malignant PC compared to NPC;41 VCAN
deregulation has been shown during the malignant trans-
formation and tumor progression;42 and MEGF9, an epi-
dermal growth factor involved in cell adhesion, receptor-
ligand interactions and tissue repairs, has been related to
local aggressiveness and soft tissue tumor.43 
Comparison of expression signatures to independent
monoclonal gammopathy datasets
In order to compare the gene expression signatures gen-
erated in the present study with previously published
data, we carried out three analyses. First, we performed a
semi-supervised approach whereby a set of genes signifi-
cantly deregulated in a multiclass comparison, including
NPC, MGUS, SMM and MM samples from the present
study, was subsequently used for identifying these sub-
groups in UAMS and Mayo Clinic datasets. As shown in
Online Supplementary Figure S1, NPC, MGUS and MM
samples showed a trend to group in separated clusters,
while SMM patients were intermingled with the other
samples. 
Then, we compared the genes differentially expressed in
MGUS, SMM and MM with regard to NPC in the three
datasets. Using a less stringent supervised analysis (q-value
< 0.05), a set of 4067, 2089 and 1583 genes differentially
expressed in clonal PC related to normal status were found
in the UAMS, Mayo Clinic and the present studies, respec-
tively. A total of 742 out of the 1583 (47%) deregulated
genes in our study were found to be significantly altered
in the UAMS and/or Mayo Clinic dataset analysis (Online
Supplementary Figure 2A). Further functional analysis of the
differentially expressed genes showed that cell death and
survival were the most significant molecular and cellular
functional categories in the three datasets based on the
deregulation of more than 300 genes. Interestingly, EIF2
signaling pathway was the most significant canonical
pathway (P<0.001) deregulated between clonal and NPC,
both in Mayo Clinic samples and in the present study. 
Finally, we sought to identify genes and molecular path-
ways commonly deregulated in the three studies when
comparing MGUS with MM. A total of 2627 out of the
3570 (74%) deregulated genes in our study were also aber-
rantly expressed in Mayo Clinic and/or UAMS dataset
analysis (Online Supplementary Figure 2B). The functional
analysis showed that cell death and survival, and cellular
growth and proliferation were the two most significant
molecular and cellular functional categories in the three
datasets, based on the deregulation of more than 700
genes (P<0.05). Among the five top canonical pathways,
EIF2 signaling and mitochondrial dysfunction were signif-
icantly altered in the Mayo Clinic and our studies.
Validation of gene expression using qRT-PCR
In order to validate some of the results, 10 genes (APAF1,
VCAN, MEGF9, SNORD55, TPI1, TERC, BAG1, BAD,
RPL7A and AKT1), selected according to their intensity
GEP in monoclonal gammopathies
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values and biological relevance, were analyzed by qRT-
PCR in 14 MGUS, 10 SMM and 10 MM samples (Online
Supplementary Figure S3). Seven out of the 10 genes
showed statistically significant differential expression
between the pre-malignant conditions and symptomatic
MM, with up- or downregulation in agreement with
microarray results. APAF1, VCAN and MEGF9 showed
significant downregulation in the transition from MGUS
to SMM and to MM, while BAD and TERC were signifi-
cantly up-regulated in the comparison between MGUS
and MM. In addition, SNORD55 and TPI1 showed pro-
gressive overexpression from MGUS to SMM and to MM
samples. 
Discussion
Gene expression profiling is a robust approach for the
accurate identification of molecular subtypes of MM.
However, the molecular definition of the different evolv-
ing steps of monoclonal gammopathies is not so clear.6,23
This is the first report that includes a large number of
patients with SMM in order to tackle the GEP analysis of
the different clonal plasma cells involved in the multistep
evolution process from NPC to symptomatic MM.
Consistent with previous reports, the comparison
between normal and clonal PC from MGUS, SMM and
MM demonstrates a clear predominance of down-regulat-
ed genes.10 Notably, the largest group of genes down-reg-
ulated in clonal PC represented small nucleolar RNAs
(snoRNAs). snoRNA are non-coding RNAs (ncRNA) that
are less well known than other ncRNAs, such as miRNAs
and siRNAs, that could be actively involved in the devel-
opment of cancer.44-47 In this setting, global downregulation
is a characteristic feature of snoRNAs in cancer cells. For
example, it has been recently reported that leukemic cells
show infraexpression of several snoRNAs.47 In addition, 9
out of 126 significant differentially expressed genes in
clonal PC were zinc finger proteins, which are a family of
transcription factors involved in governing the response to
growth factor signaling.10,48-50 CABLES1, which is a cyclin-
dependent kinase (CDK)-binding protein that plays an
inhibitor role in proliferation and/or differentiation and
whose loss of expression has been found in many human
cancers,51,52 was the most under-expressed gene in clonal
PC versus NPC. By contrast, GADD45B, which encodes a
protein, and which responds to environmental stresses by
mediating activation of the p38/JNK pathway via
MTK1/MEKK4 kinase, was the most significant up-regu-
lated gene in clonal PC. The DNA damage-induced tran-
scription of this gene is mediated by both p53-dependent
and p53-independent mechanisms.32
On the other hand, our results found a large number of
genes differentially expressed between MGUS and MM
patients, which is not consistent with a previous report
showing that most gene expression changes occur
between NPC and MGUS with less than 100 genes differ-
entially expressed between MGUS and MM.10 Probably,
the number of cases analyzed and the new version of
Affymetrix array used in our study, which interrogates
approximately 28,000 well-annotated genes, could explain
these differences. 
Since MM is a hypoproliferative tumor, it is thought
that defects in apoptosis are potentially more important in
MM pathogenesis than deregulation of genes involved in
cell growth and proliferation. This is in agreement with
the fact that several proapoptotic genes were down-regu-
lated and antiapoptotic genes up-regulated in MM, both
symptomatic and asymptomatic, compared to MGUS.
Thus, AKT1 and AKT2were found to be over-expressed in
MM versusMGUS, which may contribute to the inactiva-
tion of the apoptosis signaling observed in the myeloma
group. This finding is consistent with the contribution of
PI3K/Akt pathway to the malignant growth of MM previ-
ously described.31 Moreover, BAG1 and BAG3 were also
over-expressed in SMM versus MGUS. Members of the
BAG family are cytoprotective proteins that bind to and
regulate HSP70 family molecular chaperones. BAG1 is a
multifunctional protein involved in different cell processes
linked to cell survival. It has been reported as deregulated
in diverse cancer types, including hematology tumors.53
BAG3 is constitutively expressed in a variety of tumors,
including pancreas carcinomas, lymphocytic and
myeloblastic leukemias, and thyroid carcinomas.33
Moreover, it has been reported that downregulation of
BAG3 in vivo, which results in cell death, could be a poten-
tial anticancer therapeutic strategy.33 In addition, one of
the top 10 genes up-regulated in MM versus MGUS was
TERC. Deregulation of telomerase expression in somatic
cells may be involved in oncogenesis.54 Regarding plasma
cell dyscrasias, it has been reported that MGUS patients
exhibit normal levels of telomerase activity in their PC,
while the majority of MM and plasma cell leukemias
express high levels of telomerase activity. This finding
supports the hypothesis that activation of telomerase
could play a role in the malignant transformation from
MGUS to MM.55
Recently, an activation of MYC signature has been sug-
gested to be involved in the transformation from MGUS
to MM, since this signature was expressed in approxi-
mately 67% of MM while it was not present in NPC or
MGUS.21 Consistent with this finding, we have shown
that Myc-mediated apoptosis signaling is one of the top
canonical pathways differentiating the asymptomatic and
symptomatic myeloma. 
We have also analyzed the genes which showed a pro-
gressive modulation from MGUS to SMM and to MM
because we hypothesized that they could be directly
involved in the multistep transformation of monoclonal
gammopathies. However, a very small group of genes with
a significant progressive deregulation in the evolving stages
of the monoclonal gammopathies was found. Interestingly,
all the genes with a progressive increase were snoRNA.
Within the genes showing a progressive downregulation,
APAF1 has been previously reported to be decreased in
myeloma cells compared to NPC.41 The apoptotic peptidase
activating factor 1 (APAF1) is a gene that encodes a cytoplas-
mic protein that initiates apoptosis through activating cas-
pase 9. Activated caspase 9 stimulates the subsequent cas-
pase cascade that commits the cell to apoptosis.41 Therefore,
further investigation of the potential role of this gene on the
transformation process is warranted.
The GEP in MM are significantly related to genetic
abnormalities. Therefore, a different distribution of IGH
tx, 13q deletion and 1q gains in the MGUS, SMM and MM
groups could affect their transcriptional profile. In the
present study, the distribution according to genetic abnor-
malities was apparently similar for the three entities,
although the small number of patients has to be taken into
account.
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Finally, two approaches were carried out in order to val-
idate our data: a comparative analysis using our dataset
and two publicly available datasets obtained from two
independent groups, and a validation of the expression
levels of 10 of the most relevant genes by qRT-PCR.
Regarding validation with external data, the semi-super-
vised analysis performed particularly well, grouping most
of NPC together and distinguishing clusters that contained
mostly MM or mainly MGUS. However, the different cri-
teria used for selecting SMM samples in the three series
prevented the clustering of these cases. When the differen-
tially expressed genes were compared, the number of
commonly deregulated genes was higher in the compari-
son between MGUS and MM than between NPC and
clonal PC from all gammopathy stages. The heterogeneity
of the latter group probably contributes to such a differ-
ence. Importantly, the EIF2 signaling pathway was recur-
rently selected in the three datasets as one of the most sig-
nificantly deregulated canonical pathways. This finding
substantiates previous observations pointing out the
potential relevance of this network in MM pathogenesis,
such as a novel therapeutic approach to maximize borte-
zomib-induced apoptosis based on the inhibition of eIF2A
dephosphorylation.56 Additionally, the technical validation
by qRT-PCR of APAF1, VCAN, MEGF9, SNORD55, TPI1,
TERC, BAD expression showed consistent results with the
expression levels assessed by microarrays. This confirma-
tion supports further investigation of the functional role of
these genes in the gammopathy transformation process. 
In conclusion, our data show that although MGUS,
SMM and MM are not clearly distinguishable groups
according to their GEP, there were several signaling path-
ways and genes deregulated in the different steps of trans-
formation process. The functional analysis of some of
these deregulated genes with more biological significance
would be of great importance to understand the bases
underlying the transformation from MGUS and SMM to
symptomatic MM. 
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